Biostatistics

South Africa is short of academic statisticians: why and what can be done

Retrieved on: 
Wednesday, April 10, 2024

463 exabytes of data will be created each day globally – that’s the equivalent of 212,765,957 DVDs per day.

Key Points: 
  • 463 exabytes of data will be created each day globally – that’s the equivalent of 212,765,957 DVDs per day.
  • We are a group of academic statisticians from South African universities who have compiled a discussion paper to address these issues.
  • We have identified the factors contributing to the capacity crisis in academic statistics, including a lack of collaboration between academics in different academic statistical fields.
  • We’ve also proposed a way to improve both the quality and quantity of, primarily, doctoral candidates in the various statistical fields.

What’s in a name?

  • Over the years, a divide has emerged between those who research and lecture in applied statistics and their counterparts in mathematical or theoretical statistics.
  • Statistics departments are positioned within different faculties across various
    South African universities, for example within commerce, natural science, or engineering.
  • A doctoral candidate focused on econometrics may not realise that a biostatistician is well equipped to support and mentor them.

Assessment

  • There may be concerns that standardising assessment for what is essentially creative output (novel, innovative ideas) may be too prescriptive.
  • However, we believe that a semi-flexible assessment rubric is vital.
  • An assessment rubric is an important tool for formative assessment.

Supervisor-student relationship

  • The relationship a PhD candidate has with their supervisor is enormously important, as research from across disciplines has shown.
  • Without sufficient mentoring, early-career supervisors may not know how to nurture a healthy supervisor-student relationship.
  • They may not be aware of all of the intricacies inherent in this relationship, let alone the skills that they should be imparting to their students.

Next steps

  • To our knowledge, it is the first of its kind in the field of academic statistics.
  • Some new supervisors may use the entire guiding rubric to assist in each important area.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team

Retrieved on: 
Tuesday, April 9, 2024

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Andrew Brenner, M.D., Ph.D. (Professor-Research, Departments of Medicine, Neurology, and Neurosurgery & S & B Kolitz/CTRC-Zachry Endowed Chair Neuro-Oncology Research, Mays Cancer Center at UT Health San Antonio) has formally joined the Company in a part-time capacity. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.

Key Points: 
  • Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory.
  • In addition, Barbara Blouw, Ph.D. joins the Company as Vice President, Clinical Affairs.
  • Dr. Brenner’s academic work focuses on both clinical cancer management and the development of novel therapies to treat breast and central nervous system tumors.
  • Dr. Brenner has received numerous grants and investigational new drug approvals based on his translational research.

ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 21, 2024

WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.

Key Points: 
  • WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the year ended December 31, 2023.
  • In November, the Company announced Dr. Bruce Culleton assumed the role of the CEO and joined the ProKidney board of directors.
  • Dr. Culleton joined ProKidney in July 2023 as Executive Vice President of Clinical Development and Commercialization.
  • Mr. Periera-Kamath had previously joined ProKidney in July 2023 as Vice President of Business Development & Innovative Solutions.

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, March 20, 2024

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer.

Key Points: 
  • WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer.
  • "Dr. Kaufmann brings a wealth of experience that will be invaluable to the Vigil team,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.
  • “As we further the development of both iluzanebart and VG-3927, we will benefit from her extensive background in neurological and rare diseases, as well as her proven expertise in both domestic and global drug development.”
    Dr. Kaufmann is an accomplished biotech executive joining Vigil Neuroscience from Affinia Therapeutics where she served as Chief Medical Officer leading medical, clinical, patient advocacy and regulatory strategy.
  • “I am honored and excited to join Vigil, a company at the forefront of developing innovative treatments for rare and common neurological diseases,” said Petra Kaufmann, M.D., M.S., F.A.A.N, Chief Medical Officer of Vigil.

Ephicacy Bolsters Leadership Team with Four New Hires

Retrieved on: 
Wednesday, March 27, 2024

Ephicacy Consulting Group, Inc., (“Ephicacy”), a leading biometrics Contract Research Organization (“CRO”) and global provider of statistical programming, biostatistics, data management and real-world evidence analytics services, today announced four senior leadership appointments that further position the company for continued growth.

Key Points: 
  • Ephicacy Consulting Group, Inc., (“Ephicacy”), a leading biometrics Contract Research Organization (“CRO”) and global provider of statistical programming, biostatistics, data management and real-world evidence analytics services, today announced four senior leadership appointments that further position the company for continued growth.
  • Jim Baker as Chief Operating Officer, to oversee operations across client engagement and business development for the global company.
  • Jim brings over 35 years of experience leading bioanalytical teams at CROs and pharmaceutical companies, including at Cytel, Takeda and Amgen.
  • “I look forward to working alongside the talented team to build on this momentum, drawing on my experience helping CROs expand and scale at important moments in their lifecycle.”

Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development

Retrieved on: 
Tuesday, March 26, 2024

“We are very pleased to welcome Jeltje and Rita to our talented team.

Key Points: 
  • “We are very pleased to welcome Jeltje and Rita to our talented team.
  • Dr. Schulten received her medical degree from Erasmus University, Rotterdam, Netherlands and her MBA from the International School of Management RSM, Rotterdam, Netherlands.
  • Dr. Rita Dalal is a trained physician with extensive and diverse clinical research experience including in solid tumor oncology.
  • Previously, Dr. Dalal held clinical research scientist positions with Merck Sharp & Dohme Corp. and Eli Lilly and Company.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
  • Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.
  • Other income, net, was $1.9 million for the year ended December 31, 2023 compared to $0.4 million for 2022.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year quarter 2023 financial results on Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Analysis Group Announces Senior-Level Promotions

Retrieved on: 
Thursday, April 4, 2024

BOSTON, April 4, 2024 /PRNewswire/ -- Analysis Group , one of the largest international economics consulting firms, announces 32 promotions to vice president across nine offices.

Key Points: 
  • BOSTON, April 4, 2024 /PRNewswire/ -- Analysis Group , one of the largest international economics consulting firms, announces 32 promotions to vice president across nine offices.
  • "We are delighted to announce the largest group of consultant promotions to vice president in the history of our organization," said Martha S. Samuelson, CEO and Chairman of Analysis Group.
  • In Boston, Jonathan E. Baker specializes in the application of economic analysis to antitrust and competition, energy and environment, commercial dispute, class certification, and damages litigation matters.
  • Erica VanSant specializes in economic analysis of complex litigation matters in the areas of health care, antitrust, and IP.

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Thursday, March 28, 2024

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Thursday, March 28, 2024

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.